Plain-English translation of NCT06878144 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a research study at MD Anderson Cancer Center that aims to better understand mucormycosis and other serious fungal infections in cancer patients. Researchers will collect blood samples, tissue samples, and fluid from your lungs (if needed) to study how these infections develop and affect the body. This information will help doctors improve how they diagnose and treat fungal infections in the future.
Fungal infections like mucormycosis can be life-threatening in cancer patients, but doctors don't yet fully understand why some people develop these infections or how to best treat them. By collecting and studying samples from patients with these infections, researchers hope to develop better ways to identify who is at highest risk and create more effective treatments.
You likely qualify if…
You likely don't qualify if…
As a participant, you will be assigned to one of four groups based on your medical situation. During the study, researchers will collect blood samples, tissue samples, and possibly fluid from your lungs (called BAL fluid) using procedures your doctors already plan to do for your care. Your medical records will be reviewed to track your health outcomes. You will not receive any new medications as part of this study—this is purely a sample and data collection study to help advance future treatments.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States
Sponsor
M.D. Anderson Cancer Center
Enrollment target
~300 participants
Started
October 2025
Primary completion
December 2030
Age range
18 Years – 100 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dimitrios Kontoyiannis, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.